Fabrication, optimisation and in vitro evaluation of docetaxel and curcumin Co-loaded nanostructured lipid carriers for improved antitumor activity against non-small cell lung carcinoma

References

• Abdelwahed, W., et al., 2006. Freeze-drying of nanoparticles: formulation, process and storage considerations. Advanced drug delivery reviews, 58 (15), 1688–1713.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. 2018. Global cancer facts and figures. 4th ed. Atlanta: American Cancer Society.
   Google Scholar
• Choi, J., et al., 2011. Physicochemical characterization and in vitro hemolysis evaluation of silver nanoparticles. Toxicological sciences: an official journal of the society of toxicology, 123 (1), 133–143.
   PubMed Web of Science ®Google Scholar
• Chokshi, N.V., Khatri, H.N., and Patel, M.M., 2019. Fabrication and optimization of isoniazid loaded lipid nanoparticulate systems for the treatment of tuberculosis. Advanced science, engineering and medicine, 11 (8), 741–757.
   Google Scholar
• Chokshi, N.V., Khatri, H.N., and Patel, M.M., 2018. Formulation, optimization, and characterization of rifampicin-loaded solid lipid nanoparticles for the treatment of tuberculosis. Drug development and industrial pharmacy, 44 (12), 1975–1989.
   PubMed Web of Science ®Google Scholar
• Chou, T.C., 2006. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacological reviews, 58 (3), 621–681.
   PubMed Web of Science ®Google Scholar
• Das, S., Ng, W.K., and Tan, R.B., 2012. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? European journal of pharmaceutical sciences, 47 (1), 139–151.
   PubMed Web of Science ®Google Scholar
• ICH Expert Working Group 2005. ICH harmonized tripartite guideline: validation of analytical procedures, text and methodologies Q2 (R1). Switzerland, Geneva: ICH.
   Google Scholar
• Khatri, H., et al., 2019. Fabrication, characterization and optimization of artemether loaded PEGylated solid lipid nanoparticles for the treatment of lung cancer. Materials research express, 6 (4), 045014.
   Web of Science ®Google Scholar
• Khatri, H., et al., 2019. Formulation and optimization of paclitaxel loaded lipid nanoparticles and their in vitro cytotoxicity studies using H1299 lung cancer cell lines. Advanced science, engineering and medicine, 11 (12), 1202–1217.
   Google Scholar
• Liu, Z., et al., 2011. Preparation and evaluation of solid lipid nanoparticles of baicalin for ocular drug delivery system in vitro and in vivo. Drug development and industrial pharmacy, 37 (4), 475–481.
   PubMed Web of Science ®Google Scholar
• Mathur, P., et al., 2020. Fabrication, optimization, and in vitro evaluation of docetaxel-loaded nanostructured lipid carriers for improved anticancer activity. Journal of liposome research, 30 (2), 182–196.
   PubMed Web of Science ®Google Scholar
• Mei, L., et al., 2009. A novel docetaxel-loaded poly (ε-caprolactone)/pluronic F68 nanoparticle overcoming multidrug resistance for breast cancer treatment. Nanoscale research letters, 4 (12), 1530–1539.
   PubMed Web of Science ®Google Scholar
• Mocan, T., 2013. Hemolysis as expression of nanoparticles-induced cytotoxicity in red blood cells. BMBN, 1(1), 7–12.
   Google Scholar
• Oh, N., and Park, J.H., 2014. Endocytosis and exocytosis of nanoparticles in mammalian cells. International journal of nanomedicine, 9 (Suppl 1), 51–63.
   PubMed Web of Science ®Google Scholar
• Pawar, H., et al., 2016. Folic acid functionalized long-circulating co-encapsulated docetaxel and curcumin solid lipid nanoparticles: in vitro evaluation, pharmacokinetic and biodistribution in rats. Drug delivery, 23 (4), 1453–1468.
   PubMed Web of Science ®Google Scholar
• Peetla, C., Stine, A., and Labhasetwar, V., 2009. Biophysical interactions with model lipid membranes: applications in drug discovery and drug delivery. Molecular pharmaceutics, 6 (5), 1264–1276.
   PubMed Web of Science ®Google Scholar
• Petros, R.A., and DeSimone, J.M., 2010. Strategies in the design of nanoparticles for therapeutic applications. Nature reviews: drug discovery, 9 (8), 615–627.
   PubMed Web of Science ®Google Scholar
• Prasad, S., et al., 2014. Curcumin, a component of golden spice: from bedside to bench and back. Biotechnology advances, 32 (6), 1053–1064.
   PubMed Web of Science ®Google Scholar
• Rawal, S., and Patel, M.M., 2019. Threatening cancer with nanoparticle aided combination oncotherapy. Journal of controlled release: official journal of the controlled release society, 301, 76–109.
   PubMed Web of Science ®Google Scholar
• Rawal, S. U., and Patel, M. M., 2018. Lipid nanoparticulate systems: modern versatile drug carriers. In: Lipid Nanocarriers for Drug Targeting (pp. 49–138). Oxford, UK: William Andrew Publishing.
   Google Scholar
• Salatin, S., and Yari Khosroushahi, A., 2017. Overviews on the cellular uptake mechanism of polysaccharide colloidal nanoparticles. Journal of cellular and molecular medicine, 21 (9), 1668–1686.
   PubMed Web of Science ®Google Scholar
• Sinhmar, G.K., et al., 2018a. Process, optimization, and characterization of budesonide-loaded nanostructured lipid carriers for the treatment of inflammatory bowel disease. Drug development and industrial pharmacy, 44 (7), 1078–1089.
   PubMed Web of Science ®Google Scholar
• Sinhmar, G.K., et al., 2018b. Surface engineered lipid nanoparticle-mediated site-specific drug delivery system for the treatment of inflammatory bowel disease. Artificial cells, nanomedicine, and biotechnology, 46 (sup2), 565–578.
   PubMed Web of Science ®Google Scholar
• Souquet, P.J., and Geriniere, L., 2006. Docetaxel in non-small cell lung cancer. Therapy, 3 (5), 579–590.
   Google Scholar
• Suk, J.S., et al., 2016. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Advanced drug delivery reviews, 99 (Pt A), 28–51.
   PubMed Web of Science ®Google Scholar
• Tallarida, R.J., 2011. Quantitative methods for assessing drug synergism. Genes and cancer, 2 (11), 1003–1008.
   PubMedGoogle Scholar
• USFDA. 2017. Drug products, including biological products that contain nanomaterials – guidance for industry. Silver Spring, MD: US Department of Health and Human Services.
   Google Scholar
• Yin, N., et al., 2014. Synergistic and antagonistic drug combinations depend on network topology. PloS one, 9 (4), e93960.
   PubMed Web of Science ®Google Scholar
• Yuan, Q., et al., 2014. Docetaxel-loaded solid lipid nanoparticles suppress breast cancer cells growth with reduced myelosuppression toxicity. International journal of nanomedicine, 9, 4829–4846.
   PubMed Web of Science ®Google Scholar
• Zhang, Y., et al., 2010. DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. The AAPS journal, 12 (3), 263–271.
   PubMed Web of Science ®Google Scholar